Building the proper foundation for genomics-based patents
Building the proper foundation for genomics-based patents
复制标题
为基于基因组学的专利奠定适当的基础
DOI：
10.1038/nbt0798-683
复制
发表时间：
1998
影响因子：
46.9
通讯作者：
K. Chahine
中科院分区：
文献类型：
--
作者：
K. Chahine
随着世界上大多数药物开发公司都在为基于基因组学的药物发现做准备，重要的是要退后一步，评估这些开创性发现将获得的知识产权（IP）保护类型。目前，法律的体系正朝着一个方向发展，这将使获得DNA专利比以往任何时候都容易，但实际上不可能防止侵权。这种”一手给予，一手收回”的困境是美国专利商标局（PTO;华盛顿，DC）--给予者和法院系统--接受者之间看似矛盾的议程的结果。如果您正在考虑基于基因组知识产权的产品开发，那么了解这些趋势如何影响您潜在产品的知识产权基础是很重要的。
With most of the world's drug development companies gearing up for genomics-based drug discovery, it is important to step back and gauge the type of intellectual property (IP) protection that will be available for these pioneering discoveries. At present, the legal system is moving in a direction that will make it easier than ever to acquire DNA patents, but virtually impossible to prevent infringement. This" onehand-giveth, the-other-taketh-away" dilemma is the result of seemingly contradictory agendas between the US Patent and Trademark Office (PTO; Washington, DC)-the giver and the court system-the taker. If you are contemplating product development based on genomicsbased IP, it is important that you understand how these trends affect the IP underpinnings of your potential product.